XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde® and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer
AUSTIN, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today enrollment of the first patient into a Phase I single arm study evaluating the maximum tolerated dose of Onivyde® (Irinotecan liposome injection) and 5-fluorouracil/folinic acid in combination with MABp1 in a cohort of patients with advanced pancreatic adenocarcinoma and cachexia. The patient has begun treatment at Cedars-Sinai Medical Center under the care of Dr. Andrew Hendifar, the Study's Principle Investigator, Medical Oncology lead for the Gastrointestinal Disease Research Group and Co-Director of Pancreas Oncology at Cedars-Sinai. A total of 16 patients are expected to be enrolled in the study.
Dr. Hendifar commented, "We are excited to enroll our first patient in this novel combinatorial therapy for the treatment of advanced pancreatic cancer and cachexia. This is the first attempt to add an anti-inflammatory therapy to standard chemotherapy in an effort to improve the performance, quality of life, and survival in patients with this disease."
The study will also assess overall and progression free survival as well as evaluate the relationship between treatment tolerance and patient functional status. Various secondary measures, including changes in lean body mass, weight stability and levels of systemic inflammation will also be monitored. Onivyde will be given intravenously with MABp1 and 5-fluorouraci l /folinic acid every two weeks until disease progression.
The prognosis for advanced pancreatic cancer remains poor despite decades of studies . The 5-year survival has remained close to 5%, unchanged despite improvements in chemotherapeutics, surgical outcomes, and diagnostic techniques [1, 2]. Other than multi-agent cytotoxic therapy there have been no treatment advances for pancreatic cancer or its associated cachexia.
MABp1 was found to improve clusters of symptoms that included reduced pain, fatigue, improved appetite and increased lean body mass in advanced cancer patients. Patients that had these improvements were found to have less tumor progression, substantial reduced serious adverse events related to disease, and about a three-fold improvement in survival .
About True Human(TM) Therapeutic Antibodies
XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability.
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
- Li, D., et al., Pancreatic cancer. Lancet, 2004. 363 (9414): p. 1049-57.
- Panagiotarakou, M., et al., Use of supportive care for symptom management in pancreatic cancer: application of clinical research to patient care. Jop, 2012. 13 (4): p. 342-4.
- Hickish T., et al., MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study . Lancet Oncol. 2017 Feb;18(2):192-201.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: XBiotech, Inc via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Mandalay Resources Corporation registrerar de granskade finansiella rapporterna för det fjärde kvartalet och hela 201724.2.2018 03:04 | Pressmeddelande
TORONTO, 22 februari 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" eller "Bolaget") (TSX:MND) registrerade i dag sina granskade resultat för året som slutade den 31 december 2017. Bolagets sammanfattade och konsoliderade finansiella resultat för året som slutade den 31 december 2017, tillsammans med ledningens diskussion och analys ("MD&A") för motsvarande period finns tillgängligt under bolagets profil på www.sedar.com och på bolagets webbplats www.mandalayresources.com. För mer information: Mark Sander President och Chief Executive Officer Greg DiTomaso Director of Investor Relations Kontakt: 1.647.260.1566 Om Mandalay Resources Corporation: Mandalay Resources är ett kanadensiskt företag som arbetar med naturresurser och som har produktionstillgångar i Australien och Sverige samt underhålls- och utvecklingsprojekt i Chile. Bolaget är fokuserat på en förvärvsstrategi och att skapa nödvändig volym genom att lägga till projekt som är i ett långt utvecklat skede ell
Valero to Purchase SemLogistics Milford Haven Fuel Storage Facility23.2.2018 22:15 | Pressmeddelande
LONDON, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Valero Logistics UK Ltd, a subsidiary of Valero Energy Corporation (NYSE:VLO), and SemGroup Europe Holding L.L.C., a SemGroup Corporation company, have today signed an agreement for the purchase of SemLogistics Milford Haven fuel storage facility on the west coast of Wales. Situated across the Haven from Valero's refinery at Pembroke, the facility is one of the largest petroleum products storage facility in the United Kingdom (UK) with 8.5 million barrels of capacity for storing gasoline, gasoline blendstocks, naphtha, jet fuel, gas oil, diesel, and crude oil. Over 67 percent of the storage capacity is multiproduct or dual purpose, giving Valero the flexibility to meet customers' demands in the UK and throughout Northwest Europe. Additionally, Milford Haven will continue to operate as a third-party storage facility, offering storage options for third party customers across the European petroleum markets. "This facility complements our Pembroke
Vricon launches Telco Suite at Mobile World Congress23.2.2018 19:20 | Pressmeddelande
Visit us at MWC Booth 6L8 to learn about our 3D geodata solution McLean, Virginia, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Vricon is pleased to announce that it is launching its Telco Suite at this year's Mobile World Congress (MWC) in Barcelona. MWC participants can see a demonstration of the Telco Suite in Vricon's booth, located at #6L8. The Vricon Telco Suite is designed to help telecommunications companies navigate the rapid changes happening throughout the industry. With an increasing number of connected devices, high-definition content, and new services, the demands on networks are accelerating and growing exponentially. The Vricon Telco Suite is a cost-effective, next-generation solution that helps companies design networks for optimal performance, whether it's to densify existing 4G LTE networks, prep for 5G to empower smart homes and the Internet of Things, or work a more complex HetNet. "Mobile World Congress 2018 is the best place to see first-hand new technologies, to include Vr
Inspiration Provides Update23.2.2018 17:12 | Pressmeddelande
TORONTO, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Inspiration Mining Corporation (CSE:ISM) - Pursuant to its previous news release Feb 14, 2018 Inspiration Mining Corp. is pleased to announce that the ongoing due diligence and negotiations with Compassion Cannabis is ahead of schedule and on track. Both parties are looking forward to positive conclusion. For further information, please contact Randy Miller, Chief Executive Officer of the Corporation, at tel: 416-842-9000, www.inspirationmining.com The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This press release contains forward-looking statements based on assumptions, uncertainties and management's best estimates of future events. Actual results may differ materially from those currently anticipated. Investors are cautioned that such forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those expressed
Three Elemica Executives Named Supply Chain Pros to Know23.2.2018 15:22 | Pressmeddelande
Leading Clients on Their Digital Transformation Journey to Operational Excellence WAYNE, Pa., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Business Network for process manufacturing industries, announces that three company executives have been selected as 2018 Supply Chain Provider Pros to Know by Supply & Demand Chain Executive magazine. Armand Castro, Vice President, Application Engineering; Mark Walsh, Vice President, Global Customer Support; and Steve Troncelliti, Vice President, Global Professional Services and IT Security are this year's honored Pros to Know from Elemica. They were chosen for helping clients resolve their most significant supply chain challenges through innovative digital transformation solutions and a next-generation digital platform that lowers working capital costs, streamlines operations and drives efficiencies. "Supply chain executives want to increase their digital transformation efforts across their supply chains to gain intelligent visib
Mandalay Resources Corporation Files Audited Fourth Quarter and Full-Year 2017 Financial Statements23.2.2018 04:06 | Pressmeddelande
TORONTO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) today filed its audited financial results for the year-ended December 31, 2017. The Company's condensed and consolidated financial results for the year ended December 31, 2017, together with its Management's Discussion and Analysis ("MD&A") for the corresponding period are available under the Company's profile on www.sedar.com and on the Company's website at www.mandalayresources.com. For Further Information: Mark Sander President and Chief Executive Officer Greg DiTomaso Director of Investor Relations Contact: 1.647.260.1566 About Mandalay Resources Corporation: Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The Company is focused on executing a roll-up strategy, creating critical mass by aggregating advanced or in production gold, copper, silver and
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum